A Phase I/II Trial of Sorafenib and CCI-779 in Combination With Recurrent Glioblastoma.

Trial Profile

A Phase I/II Trial of Sorafenib and CCI-779 in Combination With Recurrent Glioblastoma.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jun 2015

At a glance

  • Drugs Temsirolimus (Primary) ; Sorafenib
  • Indications Astrocytoma; Glioblastoma; Gliosarcoma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 31 May 2013 Interim results (n=44) presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 31 May 2013 Primary endpoint 'Progression-free-survival-rate' has not been met.
    • 26 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top